Solid Malignancies Clinical Trial
Official title:
Phase I Study of Oral ST1481 Administered Once Weekly Every 3 Out 4 Weeks in Patients With Advanced Solid Malignancies.
Gimatecan® is sigma-tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors. We are conducting this study to determine the Maximum Tolerated Dose of our compound, when given as a capsule, rather than by intravenous injection.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01202370 -
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
|
Phase 1 | |
| Completed |
NCT00162136 -
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
|
Phase 1 | |
| Recruiting |
NCT05006794 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT02537418 -
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
|
Phase 1 | |
| Completed |
NCT01540526 -
Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
|
Phase 1 | |
| Recruiting |
NCT04492735 -
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
|
||
| Completed |
NCT05866354 -
To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid Malignancies
|
Phase 1 | |
| Completed |
NCT02640755 -
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
|
Phase 1 | |
| Terminated |
NCT00695370 -
Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children
|
Phase 2 | |
| Completed |
NCT02325739 -
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
|
Phase 1/Phase 2 | |
| Completed |
NCT00676299 -
A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.
|
Phase 1 | |
| Active, not recruiting |
NCT00090727 -
Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Terminated |
NCT01112397 -
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
|
Phase 1 | |
| Not yet recruiting |
NCT00751894 -
Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)
|
Phase 2 |